Liminatus Pharma, Inc. (LIMN) Stock Price & Analysis
Liminatus Pharma, Inc. (LIMN) fell 6.10% to USD 0.13 as of June 10, 2026 at 02:16 UTC, according to Nexqual real-time market data.
LIMN last closed at USD 0.14; the session ranged USD 0.13–0.15 on volume of 1,317,801 shares. Market capitalization is $5.94M, with a 52-week range of USD 0.13–33.66 (NGM). Source: Nexqual, June 10, 2026 at 02:16 UTC.
Key Statistics (as of June 10, 2026 at 02:16 UTC)
| Price | USD 0.13 |
|---|---|
| Change | ▼ 6.10% (down) |
| Previous Close | USD 0.14 |
| Open | USD 0.14 |
| Day Range | USD 0.13 – 0.15 |
| 52-Week Range | USD 0.13 – 33.66 |
| Volume | 1,317,801 shares |
| Market Cap | $5.94M |
| Exchange | NGM |
Technical Analysis (LIMN)
Nexqual's technical model rates LIMN "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:16 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.26 (neutral) |
| vs SMA50 | Below (USD 0.19) |
| MACD | -0.02 (negative) |
Analyst Ratings (LIMN)
Wall Street analysts rate LIMN "None", per Nexqual as of June 10, 2026 at 02:16 UTC.
| Consensus Rating | None |
|---|
Earnings (LIMN)
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financials & Fundamentals (LIMN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.96 |
| Total Cash | $1.91M |
| Total Debt | $1.44M |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Financial Health Score (LIMN)
Nexqual rates Liminatus Pharma, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:16 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — $2M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$12M |
| Efficiency | Mixed — No data |
Ownership (LIMN)
| Insider Ownership | +38.53% |
|---|---|
| Institutional Ownership | +3.29% |
| Shares Outstanding | 44.88M |
| Float | 29.07M |
| Short % of Float | +3.78% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
Leadership (LIMN)
Liminatus Pharma, Inc. is led by Chris Kim J.D., L.L.M. (age 64), CEO & Chairman, per Nexqual as of June 10, 2026 at 02:16 UTC.
| CEO & Chairman | Chris Kim J.D., L.L.M. (age 64) |
|---|---|
| Chief Financial Officer | Scott Dam (age 45) |
| Chief Technology Officer & Member of Scientific Advisory Board | Beom Kyu Choi (age 52) |
Major Backers & Investors (LIMN)
Notable institutional backers of Liminatus Pharma, Inc. include Citadel, Cygnus Capital Advisors, LLC, Fidelity, according to Nexqual as of June 10, 2026 at 02:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Citadel | 1.51% |
| Cygnus Capital Advisors, LLC | 0.78% |
| Fidelity | 0.24% |
| Jane Street Group, LLC | 0.16% |
| UBS Group AG | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.35% |
| Geode Capital | 0.26% |
Source: Nexqual, June 10, 2026 at 02:16 UTC.
From Liminatus Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States.
- It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KIDZ | KIDZ AI Inc. | USD 2.39 | ▼ 0.21% |
| ELPW | Elong Power Holding Limited | USD 1.16 | ▲ 51.04% |
| RBNE | Robin Energy Ltd. | USD 1.06 | ▲ 6% |
| NAMM | Namib Minerals | USD 1.93 | ▲ 0.52% |
| OSRH | OSR Holdings, Inc. | USD 0.4 | ▲ 3.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:16 UTC. This page is informational and not investment advice.